Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 41, Issue 4

Issues

Pharmacogenomics and Pharmacogenetics of Cholesterol-Lowering Therapy

Gerd Schmitz / Wolfgang Drobnik
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2003.088

Abstract

Cholesterol-lowering therapy is the central approach in the primary and secondary prevention of cardiovascular disease, the leading cause of death in industrialized countries. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are currently the most potent and widely used cholesterol-lowering drugs. Large-scale clinical trials unequivocally demonstrated the efficacy of statin treatment in reducing the risk of cardiovascular events. In general, HMG-CoA reductase inhibitors are well tolerated, although in a minority of patients severe adverse effects like myopathy or rhabdomyolysis may develop. The incidence of this potentially life-threatening side effects increases with co-adminstration of drugs that are metabolized via the same pharmacokinetic pathways or at high-dose statin therapy. The recent focus on the pleiotropic effects of statins that are more frequently observed at higher doses and the conclusion drawn from the large statin trials that low-density lipoprotein (LDL)-cholesterol is “the lower the better”, may need careful consideration in individuals at risk of adverse drug reactions. On the other hand, not all patients respond to statin therapy with a reduction in coronary heart disease (CHD) risk. It is therefore of interest to develop diagnostic test systems, which would allow to identify patients at increased risk of adverse drug reactions or patients with a lack of therapeutic effect. Beside exogenous factors, genetic variability determines the response of an individual to drug therapy and the analysis of genetic variants affecting pharmacokinetic or pharmacodynamic aspects of drug therapy is the subject of pharmacogenomics. This review summarizes current knowledge of the pharmacology and the pharmacogenomics of statin therapy.

About the article

Published Online: 2005-06-01

Published in Print: 2003-04-25


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 41, Issue 4, Pages 581–589, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2003.088.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Genovefa Kolovou, Constantinos Mihas, Katherine Anagnostopoulou, Vana Kolovou, Vasiliki Giannakopoulou, Peggy Kostakou, Marianna Stamatelatou, Sophie Mavrogeni, Dimitrios Degiannis, and Dimitri P. Mikhailidis
The Open Cardiovascular Medicine Journal, 2010, Volume 4, Number 1, Page 297
[2]
Shu-Ling Liang, Hongli Liu, and Aimin Zhou
The Journal of Immunology, 2006, Volume 177, Number 1, Page 651
[3]
Michelle R. Adams, Eddy Konaniah, James G. Cash, and David Y. Hui
American Journal of Physiology-Gastrointestinal and Liver Physiology, 2011, Volume 300, Number 1, Page G164
[4]
Estelle M. Fach, Leah-Ann Garulacan, Ji Gao, Qing Xiao, Stephen M. Storm, Yves P. Dubaquie, Stanley A. Hefta, and Gregory J. Opiteck
Molecular & Cellular Proteomics, 2004, Volume 3, Number 12, Page 1200
[5]
Dimitrios S. Christidis, Evangelos N. Liberopoulos, Anna I. Kakafika, George A. Miltiadous, Marios Cariolou, Emmanuel S. Ganotakis, Dimitri P. Mikhailidis, and Moses S. Elisaf
Journal of Cardiovascular Pharmacology and Therapeutics, 2006, Volume 11, Number 3, Page 211
[6]
Duangjai Acharaporn, Limpeanchob Nanteetip, Trisat Kanittaporn, and Ounaroon Anan
Journal of Medicinal Plants Research, 2016, Volume 10, Number 32, Page 538
[7]
Andrew J. Duncan, Iain P. Hargreaves, Maxwell S. Damian, John M. Land, and Simon J. R. Heales
Toxicology Mechanisms and Methods, 2009, Volume 19, Number 1, Page 44
[8]
Elizabeth Motunrayo Kolawole, Jamie Josephine Avila McLeod, Victor Ndaw, Daniel Abebayehu, Brian O. Barnstein, Travis Faber, Andrew J. Spence, Marcela Taruselli, Anuya Paranjape, Tamara T. Haque, Amina A. Qayum, Qasim A. Kazmi, Dayanjan S. Wijesinghe, Jamie L. Sturgill, Charles E. Chalfant, David B. Straus, Carole A. Oskeritzian, and John J. Ryan
The Journal of Immunology, 2016, Volume 196, Number 4, Page 1461
[9]
Alejandro Cuevas, César Fernández, Luis Ferrada, Tomás Zambrano, Alexy Rosales, Nicolás Saavedra, and Luis A. Salazar
Basic & Clinical Pharmacology & Toxicology, 2016, Volume 118, Number 4, Page 292
[10]
Dirk Moßhammer, Elke Schaeffeler, Matthias Schwab, and Klaus Mörike
British Journal of Clinical Pharmacology, 2014, Volume 78, Number 3, Page 454
[11]
Julie A. Johnson and Larisa H. Cavallari
Experimental Physiology, 2005, Volume 90, Number 3, Page 283
[12]
Gregory Hess, Chun-Lan Chang, and Karen Chung
Current Medical Research and Opinion, 2014, Volume 30, Number 9, Page 1743
[13]
M. Needham and F.L. Mastaglia
Neuromuscular Disorders, 2014, Volume 24, Number 1, Page 4
[14]
Catherine E de Keyser, Matthijs L Becker, André G Uitterlinden, Albert Hofman, Jan J Lous, Laure Elens, Loes E Visser, Ron HN van Schaik, and Bruno H Stricker
Pharmacogenomics, 2013, Volume 14, Number 11, Page 1295
[15]
Bonny L Bukaveckas, Roland Valdes, and Mark W Linder
Journal of Cardiothoracic and Vascular Anesthesia, 2004, Volume 18, Number 3, Page 353
[16]
Laure Elens, Matthijs L. Becker, Vincent Haufroid, Albert Hofman, Loes E. Visser, André G. Uitterlinden, Bruno Ch. Stricker, and Ron H.N. van Schaik
Pharmacogenetics and Genomics, 2011, Volume 21, Number 12, Page 861
[17]
Shawn M. Somerset
Clinical Nutrition, 2010, Volume 29, Number 3, Page 352
[18]
Maria Alice V. Willrich, Mario H. Hirata, Fabiana D.V. Genvigir, Simone S. Arazi, Ivanise M.M. Rebecchi, Alice C. Rodrigues, Marcia M.S. Bernik, Egidio L. Dorea, Marcelo C. Bertolami, André A. Faludi, and Rosario D.C. Hirata
Clinica Chimica Acta, 2008, Volume 398, Number 1-2, Page 15
[19]
Su Ying, Yan-Ming Sun, Xiao-Min Liu, Chi-Ying An, and Yin-Yuan Gao
Biochemical and Biophysical Research Communications, 2007, Volume 363, Number 2, Page 395
[20]
Gérard Siest, Jean-Brice Marteau, Sandy Maumus, Hind Berrahmoune, Elise Jeannesson, Anastasia Samara, Anne-Marie Batt, and Sophie Visvikis-Siest
European Journal of Pharmacology, 2005, Volume 527, Number 1-3, Page 1
[21]
Renata N. Freitas, Kay-Tee Khaw, Kelvin Wu, Richard Bowman, Hannah Jeffery, Robert Luben, Nick J. Wareham, and Sheila A. Bingham
Journal of the American Society of Hypertension, 2009, Volume 3, Number 4, Page 238
[22]
Kouji Kajinami, Noboru Takekoshi, Margaret E. Brousseau, and Ernst J. Schaefer
Atherosclerosis, 2004, Volume 177, Number 2, Page 219
[23]
E. Shyong Tai, Dorothea Collins, Sander J. Robins, John J. O’Connor, Hanna E. Bloomfield, Jose M. Ordovas, Ernst J. Schaefer, and Margaret E. Brousseau
Atherosclerosis, 2006, Volume 187, Number 1, Page 153
[24]
Olivier Barbier, Coralie Fontaine, Jean-Charles Fruchart, and Bart Staels
Trends in Endocrinology & Metabolism, 2004, Volume 15, Number 7, Page 324
[25]
Mario Plebani
Clinical Chemistry and Laboratory Medicine, 2010, Volume 48, Number 6
[26]
Gianfranco Cervellin, Ivan Comelli, and Giuseppe Lippi
Clinical Chemistry and Laboratory Medicine, 2010, Volume 48, Number 6
[27]
G Siest, E Jeannesson, H Berrahmoune, S Maumus, J-B Marteau, S Mohr, and S Visvikis
Pharmacogenomics, 2004, Volume 5, Number 7, Page 779
[28]
Renata N. Freitas, Kay-Tee Khaw, Kelvin Wu, Richard Bowman, Hannah Jeffery, Robert Luben, Nicolas J. Wareham, and Sheila A. Bingham
British Journal of Nutrition, 2010, Volume 104, Number 05, Page 765
[29]
Deepak Voora and Geoffrey S. Ginsburg
Current Cardiovascular Risk Reports, 2009, Volume 3, Number 6, Page 434
[30]
Robin J. Edison and Maximilian Muenke
American Journal of Medical Genetics, 2004, Volume 131A, Number 3, Page 287
[31]
Hongli Liu, Shu-Ling Liang, Sheetal Kumar, Crystal M. Weyman, Wendy Liu, and Aimin Zhou
Cancer Chemotherapy and Pharmacology, 2009, Volume 63, Number 6, Page 997
[32]
Kouji Kajinami, Hiroshi Masuya, Yachiyo Hoshiba, Kenji Takeda, Ryoko Sato, Mizuho Okabayashi, and Ernst J Schaefer
Expert Opinion on Pharmacotherapy, 2005, Volume 6, Number 8, Page 1291
[33]
James A Sikorski
Expert Opinion on Therapeutic Patents, 2006, Volume 16, Number 6, Page 753
[34]
Ruggiero Mango, Lucia Vecchione, Barbara Raso, Paola Borgiani, Ercole Brunetti, Jawahar L Mehta, Renato Lauro, Francesco Romeo, and Giuseppe Novelli
Expert Opinion on Pharmacotherapy, 2005, Volume 6, Number 15, Page 2565
[35]
Atul Tiwari, Vinay Bansal, Anita Chugh, and Kasim Mookhtiar
Expert Opinion on Drug Safety, 2006, Volume 5, Number 5, Page 651
[36]
M. Nakata, S. Nagasaka, I. Kusaka, H. Matsuoka, S. Ishibashi, and T. Yada
Diabetologia, 2006, Volume 49, Number 8, Page 1881
[37]
Anke-Hilse Maitland-van der Zee and Eric Boerwinkle
Current Atherosclerosis Reports, 2005, Volume 7, Number 3, Page 204
[38]
Robin J. Edison and Maximilian Muenke
American Journal of Medical Genetics Part A, 2005, Volume 135A, Number 2, Page 232
[39]
Rieko Tachibana-Iimori, Yasuharu Tabara, Hiroyuki Kusuhara, Katsuhiko Kohara, Ryuichi Kawamoto, Jun Nakura, Katsushi Tokunaga, Ikuko Kondo, Yuichi Sugiyama, and Tetsuro Miki
Drug Metabolism and Pharmacokinetics, 2004, Volume 19, Number 5, Page 375
[40]
Comparative and Functional Genomics, 2003, Volume 4, Number 6, Page 681

Comments (0)

Please log in or register to comment.
Log in